Hydrochloric Acid → (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-Acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid hydrochloride

HRID 361997ノート

反応式

HRID 361997 の反応式
[C:1]([N:4]1[CH2:9][CH2:8][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:6][CH2:5]1)(=[NH:3])[CH3:2].[ClH:33]>O>[ClH:33].[C:1]([N:4]1[CH2:5][CH2:6][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:8][CH2:9]1)(=[NH:3])[CH3:2]

参加物

4

実験手順

200 mg of (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid [prepared as described in step (b) above] were dissolved in 5 ml of water, after which 0.43 ml of 1N aqueous hydrochloric acid was added. The resulting mixture was worked up and purified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque), using water as the eluent. Those fractions containing the title compound were combined and lyophilized to give 149 mg of the title compound as a powder.

後処理

  1. custompurified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque),
  2. additionThose fractions containing the title compound

出典と根拠

ORDレコード
ord-96c7b297465341e885620edf08304a28
出典データセット
uspto-grants-1999_02
特許番号
US05866564

反応ノート

読み込み中…